Abstract: Provided are an inactivating agent for enveloped viruses, an inactivating composition for enveloped viruses and a method for inactivating enveloped viruses having high inactivation effects on enveloped viruses even under mild use conditions such as low concentrations or short-time contact. An inactivating agent for enveloped viruses including, as an effective component, (a) an anionic surfactant having a critical micelle concentration of 0.2×10?3 mol/L or more and 2.0×10?3 mol/L or less at 25° C. and a krafft point of 5° C. or less and having a sulfonic acid group, a sulfate group or a salt of these substituents.

Abstract: The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R??(I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.

Abstract: A method for producing an intermediate antibody regioselectively modified, which comprises: (1) mixing a solution comprising an antibody material and a solution comprising a reagent for regioselectively modifying an antibody in a micromixer to form a mixture comprising the antibody material and the reagent, wherein the reagent comprises a compound comprising an affinity substance to an antibody and a reactive group to an antibody; and (2) passing the mixture through a reaction channel to allow the antibody material and the reagent to react in the reaction channel to form a solution comprising an intermediate antibody regioselectively modified, wherein the processes (1) and (2) are continuously performed in a flow microreactor, is capable of rapidly producing a desired antibody derivative regioselectively having a functional substance or functional substances.

Abstract: The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R??(I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.

Abstract: Compounds or salts thereof represented by formula (I): wherein X indicates a leaving group, Y indicates an affinity peptide having a binding region in a CH2 domain in an immunoglobulin unit comprising two heavy chains and two light chains, M indicates a trivalent group linking the carbon atom in C?O adjacent to M and the carbon atom in C?W via a main chain portion consisting of 3 to 5 carbon atoms, O indicates an oxygen atom, S indicates a sulfur atom, W indicates an oxygen atom or a sulfur atom, N3 indicates an azide group, La indicates a bond or a divalent group, and Lb indicates a bond or a divalent group; and antibodies or salts thereof which can be prepared using such a compound or salt thereof, are useful for controlling the bonding ratio of an antibody and a modifying group within a desired range.

Abstract: The present invention provides a highly controlled complex comprising an antibody and ferritin particles. More specifically, the present invention provides the inventions of a complex or salt thereof comprising (A) one IgG antibody and (B) two human ferritin particles comprising one or more human ferritin H chains linked thereto; and methods for producing the same.

Abstract: A desired antibody or antibody composition may be obtained by modifying a thiol group chemically introduced to an antibody to obtain an antibody composition comprising (A) an antibody intermediate or a salt thereof having a bioorthogonal functional group which may be protected, which is represented by the following formula (A): AbS-L-R]n??(A) wherein Ab is a certain antibody, S is a sulfur atom, L is a divalent group, R is a bioorthogonal functional group which may be protected, and n is an integer from 1 to 8, and (B) a thiol group-introduced antibody or a salt thereof, which is represented by the following formula (B): AbSH]n??(B) wherein Ab and n are the same as formulae (A), and SH is a thiol group; and the like.

Abstract: Compounds and salts thereof represented by the following formula (I): wherein X indicates a leaving group, Y indicates an affinity peptide having a binding region to a CH2 domain in an immunoglobulin unit containing two heavy chains and two light chains, O indicates an oxygen atom, S indicates a sulfur atom, W indicates an oxygen atom or a sulfur atom, La indicates a first linker, Lb indicates a second linker, and the total number of atoms constituting a main chain in the first linker and atoms constituting a main chain in the second linker are 5 to 7, facilitate regioselective modification of an antibody with a functional substance and control of the bonding ratio of the antibody to the functional substance within a desired range.

Abstract: Provided is a vehicular control device that is provided with a switching circuit, and for opening/closing a connection between a starter including a capacitor that is to be connected to one end portion of the switching circuit and an in-vehicle battery that is to be connected to another end portion of the switching circuit by controlling an on/off state of the switching circuit. The control device includes a voltage detection unit configured to detect a voltage of the one end portion, and a control unit configured to control the switching circuit to turn off from on, and determine whether there is a failure in the switching circuit, based on a voltage detected by the voltage detection unit when a predetermined time has elapsed from when the switching circuit is controlled to turn off from on.

Abstract: Controlling the number of modifying groups introduced into a surface of ferritin affords a modified ferritin containing a human ferritin H chain, in which the human ferritin H chain contains a modifying group that is covalently bonded specifically to a cysteine residue at position 91 and/or position 103 according to a reference position of a natural human ferritin H chain.

Abstract: Provided is a vehicular control device that is provided with a switching circuit, and for opening/closing a connection between a starter including a capacitor that is to be connected to one end portion of the switching circuit and an in-vehicle battery that is to be connected to another end portion of the switching circuit by controlling an on/off state of the switching circuit. The control device includes a voltage detection unit configured to detect a voltage of the one end portion, and a control unit configured to control the switching circuit to turn off from on, and determine whether there is a failure in the switching circuit, based on a voltage detected by the voltage detection unit when a predetermined time has elapsed from when the switching circuit is controlled to turn off from on.

Abstract: Compounds having an affinity substance to an antibody, a cleavable portion, and a reactive group, or a salt thereof, are represented by the following Formula (I): A-L-B—R??(I) wherein A is an affinity substance to an antibody, L is a cleavable linker that is a divalent group comprising a cleavable portion, B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group, and R is a reactive group to the antibody, wherein the affinity substance to an antibody is a polypeptide comprising a glutamine residue (Q) at an N-terminal.

Abstract: Compounds having an affinity substance to an antibody and a bioorthogonal functional group, represented by the following Formula (I): A-L-E-B??(I) wherein A is an affinity substance to an antibody, L is a divalent group comprising a leaving group, E is a divalent group comprising an electrophilic group (i) coupled with the leaving group and (ii) having ability to react with a nucleophilic group in the antibody, B is a bioorthogonal functional group, and the leaving group has ability to be cleaved and eliminated from E by a reaction between the nucleophilic group and the electrophilic group, or a salt thereof, and the like are useful for labelling antibodies.

Abstract: Compounds having an affinity substance to an antibody, a cleavable portion, and a reactive group, represented by the following Formula (I): A-L-B-R??(I) wherein A is the affinity substance an antibody, L is a cleavable linker which is a divalent group comprising the cleavable portion, B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group, and R is the reactive group to the antibody, in which the affinity substance to an antibody is a certain peptide, or a salt thereof are useful for the modification of an antibody, particularly the regioselective modification of an antibody.

Abstract: The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R??(I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.

Abstract: In a microcomputer provided in a power supply control device, an output circuit outputs a PWM signal, in the case where a control unit determines that the value of a switch current that flows via a semiconductor switch is less than a current threshold value. In the case where the control unit determines that the switch current value is equal to or greater than the current threshold value, the output circuit outputs a switch signal output by an output unit. The switch signal instructs ON or OFF of the semiconductor switch. A drive circuit switches the semiconductor switch to ON or OFF, based on the PWM signal or switch signal output by the output circuit.

Abstract: A slotted-type rigid coupling is manufactured so that the internal-diameter dimension of a first shaft hole of a circumferentially divided shaft-fastening part is the same as that of a shaft. The first shaft hole is widened by widening force from a pressing mechanism provided with a fastening bolt, and the shaft is inserted through the first shaft hole up to a shaft insertion hole. The widening force is ceased, the first shaft hole is narrowed by fastening force from the pressing mechanism, and the shaft is securely fastened. When the shaft is securely fastened to the shaft-fastening part by the fastening bolt, eccentricity in the shaft is prevented or minimized.

Abstract: An image processing linkage system includes: an image processing apparatus and a portable terminal device connectable with each other, wherein the image processing apparatus includes a display unit, and a transmitting unit, the portable terminal device includes a display unit, a receiving unit, a display control unit, an operation information converting unit, and a transmitting unit, and the image processing apparatus receives the operation information transmitted from the portable terminal device, and executes a process corresponding to the operation information.

Abstract: An allocation apparatus configured to allocate a plurality of information processing devices to two or more management apparatuses that perform distributed management of the plurality of information processing devices, the allocation apparatus includes: an allocation unit configured to allocate an address range on a network, allocatable to a plurality of information processing devices, to the two or more management apparatuses; and an acquisition unit configured to obtain, from each of the two or more management apparatuses, management information indicating a state of the information processing device whose address belongs to a range allocated to the management apparatus, wherein the allocation unit dynamically performs allocation of the address range on the network based on the management information that has been obtained by the acquisition unit.

Abstract: An allocation apparatus configured to allocate a plurality of information processing devices to two or more management apparatuses that perform distributed management of the plurality of information processing devices, the allocation apparatus includes: an allocation unit configured to allocate an address range on a network, allocatable to a plurality of information processing devices, to the two or more management apparatuses; and an acquisition unit configured to obtain, from each of the two or more management apparatuses, management information indicating a state of the information processing device whose address belongs to a range allocated to the management apparatus, wherein the allocation unit dynamically performs allocation of the address range on the network based on the management information that has been obtained by the acquisition unit.